Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 96 от 154

Активно (без набиране) Фаза 2

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)

Pulmonary Arterial Hypertension

Researchers are looking for other ways to treat pulmonary arterial hypertension (PAH). Sotatercept is a study medicine that is designed to treat PAH. A past study, MK-7962-024 (LIGHTRAY) (NCT06664801), learned about the safety and effects of sotatercept in people with PAH. One of the goals of that study was to learn about sotatercept when given at a dose (amount) based on the weight range a person is in (weight-banded doses) compared to when given based on a person's exact weight. This is an extension study, which means people who took part in MK-7962-024 (LIGHTRAY) may be able to join this study. In this extension study, people will get weight-banded doses of sotatercept. The main goal of this study is to learn about the safety of weight-banded doses of sotatercept and if people tolerate it over a longer period of time.

Начало: 12.05.2025 Край: 16.06.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +16 Merck Sharp & Dohme LLC NCT06925750

Активно (без набиране)

Human Infection Study of H3N2 Influenza in Healthy Adults

Influenza

This study will examine how the immune system responds to a flu virus (H3N2) during and after infection in health adults aged between 18 and 50 while in an inpatient facility. The study uses a specific flu virus called the H3N2 influenza challenge virus, that was produced specifically for use in clinical research in controlled conditions. From a previous study, mild to moderate symptoms are expected. This is the first time that a flu challenge study has been undertaken in Australia.

Начало: 05.05.2025 Край: 30.06.2026 Възраст: 18–50 г. Фундаментална наука

Australia University of Melbourne NCT06972810

Активно (без набиране) Фаза 3

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

Atopic Hand and Foot Dermatitis

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with atopic hand and foot dermatitis. This study lasts up to 32 weeks, including a 6-week screening period, a 16-week treatment period, and a safety follow-up visit 12 weeks after the last dose.

Начало: 21.04.2025 Край: 01.07.2026 Възраст: от 12 г. Лечение

Argentina, Australia, Canada +5 Eli Lilly and Company NCT06921759

Активно (без набиране) Фаза 3

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Начало: 15.04.2025 Край: 20.08.2027 Възраст: от 12 г. Лечение

Argentina, Australia, Belgium +7 Janssen Research & Development, LLC NCT06934226

Активно (без набиране) Фаза 2

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Investigators are trying to find better treatments for people with HIV-1. In this clinical study, investigators want to see how well a new treatment called ISL+ULO, taken once a week, works compared to an existing treatment called BIC/FTC/TAF, which is taken every day. Investigators will check how many people still have a high level of the virus in their blood after 24 weeks. The investigators also want to understand if the new treatment, MK-8591B, is safe and how well people can handle it.

Начало: 14.04.2025 Край: 30.09.2031 Възраст: от 18 г. Лечение

Australia, Puerto Rico, Switzerland +1 Merck Sharp & Dohme LLC NCT06891066

Активно (без набиране)

ASCEND CSP IDE Study

Heart Failure Ventricular Arrythmia

This is a prospective, multi-center, global, single-arm, pivotal investigational study designed to evaluate the safety and effectiveness of the CSP ICD Lead in a subject population indicated for ICD or CRT-D therapy. The clinical investigation will enroll up to 414 subjects at up to 70 participating centers from the United States, Canada, Europe, and Asia Pacific.

Начало: 11.04.2025 Край: 01.05.2028 Възраст: 18–99 г. Лечение

Australia, Canada, France +7 Abbott Medical Devices NCT06830746

Активно (без набиране) Фаза 1

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007

Drug Resistant Epilepsy Focal Seizure

This is a randomized, double-blind, placebo-controlled study conducted in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of iQ-007. iQ-007 may be indicated for use in patients with Focal Seizures and Drug-resistant Epilepsy (DRE).

Начало: 08.04.2025 Край: 29.01.2026 Възраст: 18–55 г. Лечение

Australia iQure Australia Pty Ltd NCT06899230

Активно (без набиране) Фаза 3

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

Erythropoietic Protoporphyria (EPP) X-Linked Protoporphyria (XLP)

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Participants will complete daily questionnaires and attend study visits for assessments.

Начало: 04.04.2025 Край: 01.10.2026 Възраст: от 12 г. Лечение

Australia, Belgium, Canada +9 Disc Medicine, Inc NCT06910358

Активно (без набиране) Фаза 2

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

Celiac Disease

The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease. The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease. A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease. The expected trial duration per participant is approximately 86 weeks.

Начало: 31.03.2025 Край: 14.09.2027 Възраст: 18–64 г. Лечение

Australia, Finland, United States Teva Branded Pharmaceutical Products R&D LLC NCT06807463

Активно (без набиране) Фаза 1

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants

Atopic Dermatitis (AD)

This is a randomised, double-blinded, placebo-controlled first in human (FIH) trial to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of GB-7624. The trial will have two parts: a SAD component and a MAD component. Part A (SAD): a total of 24 healthy volunteers are planned to be enrolled across 3 SAD cohorts and will involve the administration of a single subcutaneous (SC) dose of GB-7624 (300 mg, 600 mg, or 1200 mg) or placebo on Day 1 in cohorts A1, A2, and A3. Part B (MAD): a total of 16 healthy volunteers are planned to be enrolled across 2 MAD cohorts and will involve the administration of multiple SC doses of GB-7624 (300 mg on Day 1 and Day 15 or 600 mg on Day1 and Day 15) or placebo in cohorts B1 and B2. The decision to escalate between dose levels in the SAD (Part A) and the MAD (Part B) as well as the decision to proceed from Part A to Part B will be based on safety review committee (SRC) review of prior cohorts, blinded available safety, tolerability and PK data. Study drug will be administered at the study site by trained study site personnel to ensure compliance. The administration of all trial intervention will be recorded in eCRF. Compliance will be assured by direct supervision and witnessing of trial intervention administration.

Начало: 27.03.2025 Край: 30.12.2026 Възраст: 18–65 г. Лечение

Australia Generate Biomedicines NCT06920693

Активно (без набиране) Фаза 1

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Advanced Malignant Tumors

This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.

Начало: 25.03.2025 Край: 15.10.2027 Възраст: от 18 г. Лечение

Australia, Canada, United States Bristol-Myers Squibb NCT06764771

Активно (без набиране) Фаза 2/3

A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

Chronic Hepatitis D Infection

This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.

Начало: 25.03.2025 Край: 01.09.2029 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +9 Mirum Pharmaceuticals, Inc. NCT06907290

Активно (без набиране) Фаза 3

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC). Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.

Начало: 21.03.2025 Край: 01.09.2029 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +22 Immutep S.A.S. NCT06726265

Активно (без набиране) Фаза 1

Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants

Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder) Autoimmune Encephalitis

This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ART5803 following IVIG administration in healthy participants to investigate the potential interactions between ART5803 and IVIG

Начало: 18.03.2025 Край: 24.12.2025 Възраст: 18–65 г. Лечение

Australia Arialys Therapeutics NCT06753955

Активно (без набиране) Фаза 4

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.

Начало: 14.03.2025 Край: 16.09.2027 Възраст: от 50 г. Лечение

Australia, Canada, China +9 Hoffmann-La Roche NCT06795048

Активно (без набиране) Фаза 3

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Obesity

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Начало: 12.03.2025 Край: 16.04.2027 Възраст: 18–99 г. Лечение

Argentina, Australia, Belgium +13 Amgen NCT06858839

Активно (без набиране) Фаза 3

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Viral Hepatitis

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.

Начало: 12.03.2025 Край: 01.05.2031 Възраст: 18–70 г. Лечение

Canada, Georgia, Germany +7 Vir Biotechnology, Inc. NCT06903338

Активно (без набиране) Фаза 2

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Breast Cancer

This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).

Начало: 03.03.2025 Край: 30.12.2028 Възраст: от 18 г. Лечение

Australia, Belgium, France +4 BicycleTx Limited NCT06840483

Активно (без набиране) Фаза 2

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Type 1 Diabetes Mellitus

This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy. The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo). The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.

Начало: 28.02.2025 Край: 29.04.2027 Възраст: 12–35 г. Лечение

Argentina, Australia, Brazil +5 Sanofi NCT06812988

Активно (без набиране) Фаза 2

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.

Начало: 26.02.2025 Край: 12.08.2030 Възраст: от 18 г. Лечение

Australia Fusion Pharmaceuticals Inc. NCT06909825

1 … 94 95 96 97 98 … 154